SLCO1B1, NAT2 Polymorphisms and Pharmacokinetic Variability of Rifampicin and Isoniazid in Tuberculosis Patients from Sub-Saharan Africa
Open Access
- 1 January 2022
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Journal of Tuberculosis Research
- Vol. 10 (03), 111-123
- https://doi.org/10.4236/jtr.2022.103009
Abstract
SLCO1B1 and NAT2 polymorphisms have been associated with the variability of Rifampicin and Isoniazid pharmacokinetic (PK). The objective of this study was to identify in African patients with tuberculosis (TB) or TB/HIV co-infection, the SLCO1B1 and NAT2 polymorphisms, associated with the variability of Rifampicin and Isoniazid pharmacokinetic. TB or TB/HIV co-infected patients from Benin, Guinea, Senegal, and South Africa were included in this study. The blood samples collected were stored at -80˚C until DNA extractions. The DNA extracts were then frozen at -80˚C after quality control. Double stranded DNA of the samples were quantified using a fluorimetric method to select suitable samples for the preparation of 96-well microplates, containing 100 μl of DNA extract per well at the concentration of 20 ng/μl. Illumina HumanOmniExpress-24 v1.2 microarray genotyping was performed by an external vendor. The genotyping data were analyzed and the polymorphisms with a call rate Hardy-Weinberg Equilibrium (HWE) were excluded. The correlation between significant genetic polymorphisms, the clearance, and the AUC were tested by a multiple linear regression model using the PLINK2 software. Out of 385 samples, five (05) were excluded after quality controls. After the frequency test, 384,586 SNPs failed the Hardy-Weinberg Equilibrium. Finally, 378 samples and 318,751 SNPs were included in the genetic analyses. The SLCO1B1 and NAT2 polymorphisms were associated with the variability of Rifampicin and Isoniazid PK parameters. There are SLCO1B1 and NAT2 polymorphisms carriers among TB and TB/HIV co-infected patients from Sub-Saharan Africa.Keywords
This publication has 32 references indexed in Scilit:
- The African Genome Variation Project shapes medical genetics in AfricaNature, 2014
- A Four-Month Gatifloxacin-Containing Regimen for Treating TuberculosisThe New England Journal of Medicine, 2014
- PharmGKB summaryPharmacogenetics and Genomics, 2014
- Correlation of N-Acetyltransferase 2 Genotype with Isoniazid Acetylation in Polish Tuberculosis PatientsBioMed Research International, 2013
- SLCO1B1 *15 haplotype is associated with rifampin-induced liver injuryMolecular Medicine Reports, 2012
- Arylamine N-acetyltransferase 2 genotypes in a Mexican populationEvolution, 2012
- The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing ImplicationsAntimicrobial Agents and Chemotherapy, 2011
- Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin ConcentrationsAntimicrobial Agents and Chemotherapy, 2010
- Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable AbsorptionAntimicrobial Agents and Chemotherapy, 2008
- Tuberculosis therapy: past, present and futureEuropean Respiratory Journal, 2002